Concord Biotech is a listed company as of August 18, 2023. It listed on the BSE and NSE today, August 18, 2023, at a price of ₹863 per share, a 21% premium over its issue price of ₹741 per share. The company raised ₹1,551 crore through its IPO.
The high demand for Concord Biotech shares is due to a number of factors, including:
- The company’s strong financial performance. Concord Biotech reported a net profit of ₹100 crore in the financial year 2022-23.
- The company’s strong pipeline of products. Concord Biotech is developing a number of new drugs, including treatments for cancer, diabetes, and heart disease.
- The growing demand for biopharmaceuticals in India. The Indian biopharmaceutical market is expected to grow at a CAGR of 15% over the next few years.
However, investors should also be aware of the risks associated with investing in Concord Biotech shares. These risks include:
- The company is still in the early stages of development. There is a risk that the company may not be able to successfully commercialize its products.
- The company faces competition from other biopharmaceutical companies.
- The company’s shares are volatile and prices can fluctuate significantly.
Overall, Concord Biotech is a promising company with a strong growth potential. However, investors should carefully consider the risks before investing in the company’s shares.